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ASQLAbstract Introduction: Smoking was associated with an earlier onset of back pain, higher disease
activity, worse functional status and quality of life in patients with AS.
Aim of the work: To detect the relationship between smoking and disease outcome measures in
AS patients.
Patients and methods: A total of 30 patients with disease duration of 9.6 ± 5.8 years. They were
divided into 2 groups according to their smoking status, the mean age of non-smokers 11/30
patients (36.7%) and smokers 19/30 patients (63.3%) was (29 ± 8.4 years vs 34.9 ± 8.1 years
respectively) and their disease duration was (6.6 ± 3.9 years vs 8.3 ± 6.1 years respectively).
Results: The smokers showed longer morning stiffness duration (p= 0.02), less spinal mobility
(p= 0.02) and less chest expansion (p= 0.02). Also they had a higher disease activity index (BAS-
DAI) (p= 0.03) and poorer quality of life index (ASQL) (p= 0.03), while there was no statistically
signiﬁcant difference between the 2 groups regarding the physical activity index (BASFI)
(p= 0.07). There was a positive signiﬁcant correlation between smoking duration and age
(p< 0.001, r= 0.9). Disease duration was found to be a signiﬁcant independent risk factor for
the decrease of chest expansion (p= 0.04).
Conclusion: This study proved some of the adverse effects of smoking on ankylosing spondylitis
patients mainly on the domains of disease activity and quality of life. So we recommend the cessa-
tion of smoking in every AS patient as part of the treatment plan.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Ankylosing spondylitis (AS) is a chronic inﬂammatory multi-
system disorder affecting 0.1–2% of the general population,the age of onset ranges between 15 and 35 years [1]. The ﬁrst
historical description of AS did not appear in the literature
until 1559 when Realdo Colombo provided an anatomical
description of two skeletons with abnormalities typical of AS
in his book De Re Anatomica [2]. The spectrum of joint
involvement in seronegative SpAs should not be limited to
sacroiliitis [3]. The condition involves inﬂamed sacroiliac joints
and the axial skeleton, causing inﬂammatory pain and stiff-
ness. Other systems affected include peripheral arthritis, enthe-
sitis [4] and extraarticular features such as inﬂammatory bowel
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diac pathology [4].
The severity of AS has been affected by several factors as
age of onset, presence of co morbid conditions, involvement
of peripheral joints, current and past physical activity at work,
frequency of back exercise and smoking. It has been reported
that smoking has a negative impact on disease activity and
functional ability in AS [6] with more severe radiographic dam-
age [7]. Incident AS was associated with current smoking. This
suggests that smoking should be further discouraged in those
at a higher AS risk, e.g., with a family history or carrying
HLA-B27 [8].
Smoking is one of the most serious health problems, as it is
a well-established risk factor for developing RA [9], systemic
lupus erythematosus, inﬂammatory bowel disease [10], and
has also been associated with phenotypic variations in AS
[11]. However, it has been reported that no signiﬁcant differ-
ence was found between smokers and nonsmokers regarding
the intima-media thickness in a study on Egyptian Behc¸et’s
disease patients [12]. Smoking has a recognized inﬂuence on
the disease course of seronegative spondyloarthritis and is
associated with poor long term outcome in AS patients [13].
Absenteeism from work in AS patients was associated with
current smoking status [14].
Exposure to cigarette smoke results in the depression of
phagocytic and antibacterial functions of alveolar macro-
phages [15], decrease in primary antibody response [16],
T-cell attenuation by impairing the antigen receptor-mediated
signaling [17] and a decline in TNF production [18].
This cross sectional study aimed to clarify the relationship
between smoking and disease outcome measures in AS
patients.2. Patients and methods
2.1. The demographical data of the examined patients
We studied 30 male AS patients diagnosed according to the
modiﬁed Ankylosing Spondylitis Assessment Study (ASAS)
group criteria [19]; their mean age was 32.7 ± 8.6 years and
a disease duration of 9.6 ± 5.8 years. They were divided into
2 groups according to the smoking status.
2.2. The assessment measures of the examined patients
The impact of smoking on disease duration, clinical ﬁndings,
laboratory results, structural damage using modiﬁed New
York criteria-radiological scoring [20], disease activity using
Bath Ankylosing Spondylitis Disease Activity Index (BAS-
DAI) [21], physical function using Bath Ankylosing Spondyli-
tis Functional Index (BASFI) [22] and patient’s quality of life
using Ankylosing Spondylitis Quality of Life (ASQL) ques-
tionnaire [23] was analyzed. Ophthalmological examination
including fundus and slit lamp was done to all patients, in
addition to full laboratory investigations and musculoskeletal
examination. All subjects were informed about the aim of
the study and gave their consent and the study approved by
the local ethics committee. Patients were collected from the
Rheumatology and Rehabilitation Department, Cairo Univer-
sity Hospitals.Statistical analysis: Data were collected, tabulated and ana-
lyzed by SPSS package version 15 (SPSS corporation USA),
qualitative data were presented in the form of number and per-
cent and quantitative data were presented in the form of mean
and standard deviation. Correlation between variables was
performed using Pearson’s correlation test. A signiﬁcant corre-
lation was considered if p< 0.05. Statistical differences
between groups were tested using the Chi-square test for qual-
itative variables, independent sample t-test for quantitative
variables. P-values less than 0.05 were considered statistically
signiﬁcant. Stepwise logistic regression analysis was performed
to estimate the association between chest expansion and age,
disease duration and smoking duration. P< 0.05 was consid-
ered statistically signiﬁcant.
3. Results
The 30 AS patients were divided into 2 groups according to
their smoking status into 19/30 smokers (63.3%); smoked 1
and 2 pack/day with a mean age of 29 ± 8.4 years and 11/30
non-smokers (36.7%) with a mean age of 34.9 ± 8.1 year. Dis-
ease duration was 6.6 ± 3.9 and 8.3 ± 6.1 years respectively.
The comparison between smokers and non-smokers regard-
ing laboratory results and radiological ﬁndings showed no sig-
niﬁcant difference while the smoker group had a longer
duration of morning stiffness (p= 0.02), less spinal mobility
using the Scho¨ber test (p= 0.02) and less chest expansion
(p= 0.002). Data are shown in Table 1. 3/19 (15.8%) of the
smoker group were on sulfasalazine vs 2/11 (18.2%) of the
non-smokers and 4/19 (21.1%) of the smokers were on anti-
TNF therapy vs 3/11 (27.3%) of the non-smokers with no
statistically signiﬁcant difference (p= 0.6 and p= 0.9
respectively) and all of the examined patients were on NSA-
IDs. Ophthalmological examination revealed the absence of
uveitis in all the patients.
As regards the disease outcome; the smokers group had a
higher BASDAI score (p= 0.03) and poorer quality of life
assessed by ASQL questionnaire than those of non-smokers
with signiﬁcant statistical difference, while the BASFI did
not show any signiﬁcant difference between both groups
(Table 2).
There was a signiﬁcant negative correlation between chest
expansion and age (p= 0.01, r= 0.6), smoking duration
(p= 0.03, r= 0.5) (Figure 1) and disease duration
(p= 0.03, r= 0.5). But stepwise logistic regression analysis
revealed that only disease duration was the risk factor for
impairment of chest expansion (Table 3).
4. Discussion
The present study revealed that smokers had a longer duration
of morning stiffness, less spinal mobility measured by the Scho¨-
ber test and less chest expansion with no signiﬁcant difference
regarding age and disease duration compared to the non-smo-
ker group. This matched the results of Chen et al. who found
adverse smoking effect on the Scho¨ber test and chest expansion
[24]. Smoking was found to have a possible effect on outcome in
AS. In a study on 31 non-smokers, 12 ex-smokers, and 10
smokers with AS, there were statistically signiﬁcant differences
in the outcome between smokers and non-smokers for ﬁnger
ﬂoor distance (p< 0.01), Scho¨ber test (p< 0.01), total spinal
Table 1 Comparison between smoker and non-smoker ankylosing spondylitis patients regarding demographic, clinical and
laboratory features as well as the radiological score of sacroiliitis.
Parameter mean ± SD Ankylosing Spondylitis patients (n= 30) P value
Smokers (n= 19) Non-smokers (n= 11)
Age (years) 34.9 ± 8.1 29 ± 8.4 0.2
Disease duration (years) 11.3 ± 6.1 6.6 ± 3.9 0.3
Morning stiﬀness (min) 76.6 ± 58.3 41 ± 23.4 0.02*
Scho¨ber test (cm) 1.4 ± 1.2 2.5 ± 1.0 0.02*
Chest expansion (cm) 3.4 ± 1.2 5.0 ± 1.1 0.002*
Peripheral joint aﬀection N (%) 11 (57.9) 4 (36.4) 0.5
Hemoglobin (gm/dl) 12.9 ± 1.2 12.6 ± 1.5 0.5
White blood cells (103/mm3) 6.7 ± 1.5 7.8 ± 1.4 0.8
Platelets (103/mm3) 260 ± 13.7 272.7 ± 36.9 0.6
ESR (mm/h) 26.2 ± 8.9 23.8 ± 10.4 0.5
Aspartate transferase (U/L) 19.7 ± 7.7 17.2 ± 5.2 0.3
Alanine transferase (U/L) 17.9 ± 6.43 16.1 ± 8 0.5
Serum creatinine (mg/dl) 0.8 ± 0.2 0.71 ± 0.14 0.3
Radiological score of sacroiliitis N (%)
Grade 0 (n= 0) 0 (0) 0 (0) 0.9
Grade 1 (n= 0) 0 (0) 0 (0)
Grade 2 (n= 6) 3 (50) 3 (50)
Grade 3 (n= 13) 8 (61.5) 5 (38.5)
Grade 4 (n= 11) 8 (66.7) 3 (27.3)
ESR: erythrocyte sedimentation rate.
* Signiﬁcant with p< 0.05.
Table 2 Comparison between smoker and non-smoker ankylosing spondylitis patients regarding disease activity, physical function
and quality of life.
Measurement tool Ankylosing Spondylitis patients (n= 30) P value
Smokers (n= 19) Non-smokers (n= 11)
BASDAI 6.4 ± 1.6 5.0 ± 1.5 0.03*
BASFI 6.5 ± 2.2 4.8 ± 2.4 0.07
ASQL 13.6 ± 4.5 10.1 ± 3.3 0.03*
BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Ankylosing Spondylitis Functional Index, ASQL: Ankylosing
Spondylitis Quality of Life.
* Signiﬁcant with p< 0.05.
Impact of smoking on disease outcome in spondylitis patients 187movement (p< 0.001), occiput-wall distance (p< 0.01) and
stiffness (p< 0.01) [13].
In the present work there was no signiﬁcant difference in
the age or disease duration. In agreement was the work of
another study on non-smoking, ex-smoking and smoking AS
patients and it was found that there was no statistically signif-
icant difference among them with regard to disease duration or
age at onset [13].
In the current work there was no signiﬁcant difference
between the two groups regarding radiological damage. In
agreement were the results of another study that found that
there was no statistically signiﬁcant difference between those
with and without radiographic sacroiliitis regarding smoking
status [25]. On the contrary, there were statistically signiﬁ-
cant differences in the outcome between smokers and non-
smokers for spine X-ray scores [13] and in contrast to the
results of Chen et al. [24] who found signiﬁcant structural
damage with smokers and this may be explained as they
used MRI for diagnosing their patients which is more accu-
rate than the plain X-rays that we used. Also our results did
not match with those of Poddubnyy et al., where they foundsigniﬁcant structural damage and worsening of the radiolog-
ical score with new syndesmophytes formation over 2 years
follow up in smoker AS patients and this may explain the
dissimilarity with our result as they followed their patients
over 2 years while our study was cross sectional [26].
Another study reported that cigarette smoking was indepen-
dently associated with spinal radiographic progression in
patients with early axial SpA [27].
The higher BASDAI index in the smoker group matches
the results of Mattey et al. [28]. Same result was reached by
Chung et al. [29] and Chen et al. [24] as they found that
BASDAI values were higher in smoking AS patients, but
this difference did not show statistical signiﬁcance. Also
another study matched our results; it was conducted by
Kaan and Freda who compared between smokers and
non-smokers at a cross-sectional level and their results
revealed a higher disease activity with higher BASDAI in
the smokers group [11].
Smoking was also associated with poorer quality of life,
this agreed with Mattey et al. [28] study who found that
ASQL domain was higher in the smokers group compared
Figure 1 Correlation between chest expansion and smoking
duration in ankylosing spondylitis smoker patients (n= 19).
Table 3 Predictive values of impaired chest expansion in
ankylosing spondylitis patients.
Predictors OR (95% CI) P value
Disease duration 0.18 to 0.11 0.04*
Age 0.23–0.5 0.2
Smoking duration 0.15–0.16 0.9
* Signiﬁcant with p< 0.05.
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Freda [11] also came in concordance with ours. In recent
studies, smoking negatively affected the quality of life in
AS patients [30,31].
When we assessed the patient’s functional status we found
that BASFI scores were higher in smokers but without statis-
tically signiﬁcant difference between 2 groups. This result
was in concordance with Chen et al. [24] who found that
BASFI scores were higher in smokers but without statistical
signiﬁcant difference. On the contrary Mattey et al. [28] found
that smokers had worse functional status with signiﬁcant
higher BASFI regardless if the patient is still smoking or quit
smoking. Also Averns et al. [13] and Chung et al. [29] revealed
that smoking was associated with poorer functional status; our
contradicting results may be due to smaller studied population
and the need for longer period of follow up for assessing phys-
ical function while our study was cross sectional.
Conclusion: Smoking is one of the most concerned public
health problems; in the current study it was found that smoker
AS patients had higher disease activity, poorer quality of life
and worse clinical parameters. We strongly support smoking
cessation in patients with AS and this could be achieved by
promoting specialist smoking cessation clinics and providing
more information during clinic appointments about the
negative effects of smoking.Conﬂict of interest
No conﬂict of interest.
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